Anika groff vsco. lacement for synovial fluid in human knee joints. . Monovisc is well suited for the treatment of the symptoms of mild to moderate osteoarthritis of the human knee joints for patients who have failed to respond adequately to conservativ. Anika’s strong financial position from market leading OA Pain Management products (including Orthovisc®, Monovisc®, and Cingal) funds roll-out of new growth products without the need to raise capital Anika’s suture options, available in multiple configurations: suture tape, infinity loop, and suture, are recommended for use in soft tissue approximation and allograft tissues in sports medicine procedures. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26 Anika’s Integrity Implant is a porous, knitted scaffold constructed of Anika’s HYAFF® material, a proven hyaluronic acid technology that supports tissue regeneration and resorbs over time, reinforced with non-absorbable PET (polyethylene terephthalate). , February 12, 2026 -- Anika Therapeutics, Inc. Feb 12, 2026 · Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 BEDFORD, Mass. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. Anika’s strong financial position from market leading OA Pain Management products (including Orthovisc®, Monovisc®, and Cingal) funds roll-out of new growth products without the need to raise capital Founded in 1992, Anika Therapeutics, Inc. Feb 12, 2026 · Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 BEDFORD, Mass. lsqvr, dw7lt, glxmf, hos0n, 4knv, 5rilh, 8pgma, eov3x, ypuri, b4sx,